Salix Pharmaceuticals Ltd. (SLXP) Monday said FDA has extended the Prescription Drug User Fee Act goal date for the Agency's Priority Review of the efficacy supplement to NDA 21-361 for XIFAXAN 550 mg Tablets by three months to March 7, 2011. The previous goal date was December 7, 2010.
XIFAXAN, or rifaximin 550 mg is indicated for reduction in risk of overt hepatic encephalopathy recurrence in patients of or greater than 18 years of age. It is used for the proposed indication of the treatment of non-constipation irritable bowel syndrome and IBS-related bloating.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.